Jump to content

Tezosentan

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by SMILESmaster (talk | contribs) at 06:33, 1 October 2018 (fixed SMILES). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Tezosentan
Space-filling model of the tezosentan molecule
Clinical data
ATC code
  • none
Identifiers
  • N-[6-(2-Hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2H-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-propan-2-ylpyridine-2-sulfonamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC27H27N9O6S
Molar mass605.624 g·mol−1
3D model (JSmol)
  • O=S(=O)(c1ncc(cc1)C(C)C)Nc3nc(nc(OCCO)c3Oc2ccccc2OC)c5ccnc(c4n[nH]nn4)c5
  • InChI=1S/C27H27N9O6S/c1-16(2)18-8-9-22(29-15-18)43(38,39)34-26-23(42-21-7-5-4-6-20(21)40-3)27(41-13-12-37)31-24(30-26)17-10-11-28-19(14-17)25-32-35-36-33-25/h4-11,14-16,37H,12-13H2,1-3H3,(H,30,31,34)(H,32,33,35,36) checkY
  • Key:TUYWTLTWNJOZNY-UHFFFAOYSA-N checkY
  (verify)

Tezosentan is a non-selective ETA and ETB receptor antagonist.[1] It acts as a vasodilator and was designed as a therapy for patients with acute heart failure. Recent studies have shown however, that tezosentan does not improve dyspnea or reduce the risk of fatal or nonfatal cardiovascular events.[2]

References

  1. ^ Urbanowicz, W; Sogni, P; Moreau, R; Tazi, K A; Barriere, E; Poirel, O; Martin, A; Guimont, M C; Cazals-Hatem, D; Lebrec, D (2004). "Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats". Gut. 53 (12). BMJ Publishing Group Ltd & British Society of Gastroenterology: 1844–1849. doi:10.1136/gut.2003.036517. PMC 1774327. PMID 15542526.
  2. ^ "Tezosentan does not appear to improve symptoms for patients with acute heart failure". Medical Studies/Trials. news-medical.net. 7 Nov 2007. Retrieved 2007-11-24.

Template:Peptidergics